Download Report

product specifications
natural solutions + clinical results
www.bioclinicnaturals.com
Choles-Restore ACC™
Advanced Cholesterol Control
with Intermediate Release Niacin, Sytrinol®
& Hibiscus
Choles-Restore ACC™
Advanced Cholesterol Control
60 tablets
Code: 9320
Product Summary
A unique combination of cholesterol lowering agents, Choles-Restore AAC targets
atherogenic lipids as well as endothelial health, with ingredients proven to lower the risk
of cardiovascular events. Niacin is a pleotropic molecule, reducing levels of all atherogenic
particles containing apoB, including LDL-C, triglycerides, and Lp(a).1 Although niacin is
the only known substance to significantly increase HDL cholesterol, a large body of
clinical evidence has found it significantly reduces both cardiovascular events and major
coronary heart disease, potentially through unrelated mechanisms.2 It improves
endothelial function, and reduces carotid intima-media thickness and C-reactive protein
among participants with the metabolic syndrome.3,4 The intermediate release form is the
treatment of choice, as it is associated both with lower hepatic toxicity as well as reduced
flushing.
Choles-Restore AAC also contains Sytrinol, a unique combination of citrus flavonoids and
palm tocotrienols shown to inhibit apoB synthesis, as well as apoB containing lipids.5
Citrus flavonoids also blunt inflammation in key metabolic tissues, and normalize insulin
sensitivity.6 Lastly, Hibiscus sabdariffa has anti-hyperlipidemic effects, reduces LDL
peroxidation, and stimulates cholesterol removal from macrophages by a unique
mechanism,7,8 completing this synergistic anti-atherogenic blend.
Unique Features • Provides niacin (nicotinic acid) as intermediate release form; extensively
documented improvement in dyslipidemia and inflammation
• High potency dosing, with 500 mg nicotinic acid, 75 mg Sytrinol, and 62.5 mg
Hibiscus sabdariffa per tablet, all clinically relevant dosages
• Intermediate release form of niacin avoids both the hepatotoxicity and cutaneous
flushing common to other forms
• Well-suited for patients with mixed dyslipidemias, considering multiple lipidmodifying and anti-inflammatory effects of diverse anti-atherogenic ingredients
FOR PROFESSIONAL USE ONLY. These statements have not been evaluated by the Food and Drug Administration. This product is not
intended to diagnose, treat, cure or prevent any disease. © All Rights Reserved Bioclinic Naturals™ 2014. February 2014. 50284
Head office Bioclinic Naturals™, 1550 United Boulevard, Coquitlam, BC, Canada V3K 6Y2
U.S. Distribution office 14224 167th Avenue SE, Monroe, WA, USA 98272
customer service 1 877 433·9860 · fax 1 877 433·9862 · email [email protected]
Actual size: 21.38 mm x 9.84 mm
Feature: Advanced Cholesterol Control
ACC
Supplement Facts
TM
ntrol
cin,
natural solutions + clinical results
www.bioclinicnaturals.com
Serving Size 1 Tablet
Amount Per Serving
Niacin (nicotinic acid)
500 mg
Calcium (dicalcium phosphate)
133 mg
Sytrinol®
75 mg
Orange Extract (Citrus aurantium or Citrus nobilis)
(peel) (24.3 mg polymethoxylated flavones)
67.5 mg
Palm Extract (Elaeis guineensis) (seed oil)
(1.125 mg tocotrienols)
7.5 mg
Hibiscus sabdariffa 4:1 Extract (flower)
62.5 mg
(Standardized to contain 6% anthocyanins)
% Daily Value
2,500%
10%
**
**
**
**
** Daily Value not established.
T
Other ingredients: Dicalcium phosphate dihydrate, modified cellulose, microcrystalline
cellulose, coating (carbohydrate gum [cellulose], glycerin), magnesium stearate
(vegetable grade).
Sytrinol® is a registered trademark of NPI, LLC.
Contains
noPatent
artificial
colors,
or sweeteners;
For Sytrinol® US
information,
pleasepreservatives,
visit www.sytrinol.com
no dairy, sugar, wheat, gluten, yeast, soy, egg, fish, shellfish, animal
products, salt, tree nuts, or GMOs. Suitable for vegetarians/vegans. Sealed for your protection. Do not use if seal is broken. For freshness, store in a cool, dry place.
Suggested Usage: 1 tablet per day with a meal or as directed by a health care professional. Begin dosing at 1 tablet every night for
4 weeks, and if well-tolerated, increase dose by 1 tablet every 4 weeks. Target dose is 1500 mg to 2000 mg niacin per day. Low-fat
snacks at time of administration may help prevent adverse R0
effects, though hot or spicy foods should be avoided.
Choles-Restore ACC is a synergistic formula combining three clinically proven natural ingredients that support normal cholesterol
metabolism via different, but complementary mechanisms.* The intermediate-release tablet allows for the ingredients to be absorbed
steadily over a six to eight hour period thus reducing the issue of flushing of the skin caused by niacin.* A factor in the maintenance of
good health.* Helps to prevent niacin deficiency.*
Contraindications: Most people should not experience flushing when using this product. However, a few individuals sensitive to nicotinic
acid may experience some flushing of the skin that is generally mild and transient. Safety at therapeutic doses has not been established
during pregnancy or lactation. Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Do not exceed the
recommended dose except on the advice of a health care professional. All forms of niacin have been associated with hepatotoxicity. This
occurs at a significantly lower frequency with the extended and intermediate release forms than the sustained release, yet liver function
tests should be monitored.9 Niacin therapy should be avoided in patients with either peptic ulcer disease or gout and/or elevated serum
uric acid levels, and used with caution in those with renal impairment. Niacin has been shown to be safe for diabetics, though marginal
but non-significant and non-lasting elevations in serum glucose have occurred, suggesting monitoring of glycemic control may be desirable. Do not take on an empty stomach. Keep out of reach of children.
Drug Interactions: Favorable effects have been well-documented when used in conjunction with statin drugs for dyslipidemia, and may
allow for reduced dosing of statins.10 Antioxidant supplementation (vitamins E and C, beta-carotene, and selenium) may blunt the favorable effect of niacin on HDL levels. Evidence exists for a synergistic effect on glycemic control when used with chromium.11
References:
1.
Creider JC, Hegele RA, Joy TR. Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol. 2012 Sep;8(9):517-28. doi: 10.1038/nrendo.2012.22.
2.
Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013 Jan 29;61(4):440-6. doi: 10.1016/j.jacc.2012.10.030.
3.
Sahebkar A. Effect of niacin on endothelial function: A systematic review and meta-analysis of randomized controlled trials. Vasc Med. 2014 Jan 3. [Epub ahead of print]
4.
Thoenes, M. et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int. J. Clin. Pract. 61, 1942–1948 (2007).
5.
Roza JM, Xian-Liu Z, Guthrie N. Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects. Altern Ther Health Med. 2007 Nov-Dec;13(6):44-8.
6.
Assini JM, Mulvihill EE, Huff MW. Citrus flavonoids and lipid metabolism. Curr Opin Lipidol. 2013 Feb;24(1):34-40. doi: 10.1097/MOL.0b013e32835c07fd.
7.
Chen JH, Wang CJ, Wang CP, Sheu JY, et al. Hibiscus sabdariffa leaf polyphenolic extract inhibits LDL oxidation and foam cell formation involving up-regulation of LXRα/ABCA1 pathway. Food Chem. 2013 Nov 1;141(1):397-406. doi:
10.1016/j.foodchem.2013.03.026.
8.
Hopkins AL, Lamm MG, Funk JL, Ritenbaugh C. Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies. Fitoterapia. 2013 Mar;85:84-94. doi: 10.1016/j.
fitote.2013.01.003.
9.
Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm. 2003 Jul 1;60(13 Suppl 2):S9-14;
10. Toth PP, Thakker KM, Jiang P, et al. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vasc Health Risk Manag. 2012;8:39-44.
11. Urberg M, Zemel MB. Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans. Metabolism 1987;36:896-9.
PRODUCT OF CANADA
Manufactured for and distributed
· GUARANTEED ·
by Bioclinic NaturalsTM U.S.
14224 167th Ave. SE,
Bioclinic Naturals products are guaranteed to meet or exceed Good Manufacturing
Practices (GMP) of the Canadian Government and the Therapeutic Goods Administration
(TGA) regulations of Australia—among the world’s highest standards for natural products.
Monroe WA, USA 98272
www.bioclinicnaturals.com
Recyclable container
FOR PROFESSIONAL USE ONLY. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
© All Rights Reserved Bioclinic Naturals™ 2014. February 2014. 50284
Head office Bioclinic Naturals™, 1550 United Boulevard, Coquitlam, BC, Canada V3K 6Y2 U.S. Distribution office 14224 167th Avenue SE, Monroe, WA, USA 98272
customer service 1 877 433·9860 · fax 1 877 433·9862 · email [email protected]
1 877 433·9860